Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?

Pack A, Grunstein R, Mokhlesi B, Ryan S, Schwab R, Gozal D. What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)? Sleep

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity N Engl J Med

Glucagon-like peptide 1 (GLP-1) receptor agonists’ use during pregnancy: Safety data from regulatory clinical trials

Parker CH, Slattery C, Brennan DJ, le Roux CW. Glucagon-like peptide 1 (GLP-1) receptor agonists’ use during pregnancy: Safety data from regulatory clinical trials Diabetes Obes Metab

Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes

Al-Najim W, Raposo A, BinMowyna MN, le Roux CW. Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes Nutrients

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, Lingvay I, Lyndgaard CB, Rosenstock J, Pedersen SD; REDEFINE 2 Study Group. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes N Engl J Med
Insulin Resistance & Diabetes

Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss

Heald AH, Reynolds G, Nash I, Boyle O, Daly C, Longson D, O'Shea D, Ingram J, Holt R, Firth J, Stedman M, Syed A, de Hert M. Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss Adv Ther

Why do patients with obesity discontinue glucagon-like peptide 1 analogues?

Almohaileb FI, le Roux CW, Crotty M. Why do patients with obesity discontinue glucagon-like peptide 1 analogues? Diabetes Obes Metab

GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials

Romariz LM, de Melo AAC, Finnegan E, Mesquita Y, Janovsky CCPS. GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials Pediatr Res

Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide

Linetzky B, Sattar N, Verma S, Krumholz HM, Xie CC, Hoffmann HT, Zimner-Rapuch S, Torcello-Gómez A, Stefanski A. Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide Ann Intern Med

Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis

Pan XH, Tan B, Chin YH, Lee ECZ, Kong G, Chong B, Kueh M, Khoo CM, Mehta A, Majety P, Grandhi GR, Dimitriadis GK, Foo R, Chew NWS, Le Roux CW, Mamas MA, Chan MY. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis Obesity (Silver Spring)

Older posts

Newer posts

← Previous Page1 Page2 Page3 Page4 … Page27 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2026 ASOI